Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
NX-2127 (BTK Degrader) |
Targeted Protein Degrader | Hematologic | ||
|
Molecule
NX-2127 (BTK Degrader)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
||||
NX-5948 (BTK Degrader) |
Targeted Protein Degrader | Hematologic | ||
|
Molecule
NX-5948 (BTK Degrader)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
||||
Obrixtamig |
Bispecific T-Cell Engager, DLL3 x CD3 | Solid Tumour | ||
|
Molecule
Obrixtamig
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Bispecific T-Cell Engager, DLL3 x CD3 |
||||
Ociperlimab |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Ociperlimab
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
Omburtamab |
Radiolabelled Anti-B7-H3 Monoclonal Antibody (I-131) | Solid Tumour (Neuroblastoma) | ||
|
Molecule
Omburtamab
Therapeutic Category
Targeted Therapy (Investigational Antibody)
Oncology Type
Solid Tumour (Neuroblastoma)
Drug Class / Mechanism
Radiolabelled Anti-B7-H3 Monoclonal Antibody (I-131) |
||||
Otlertuzumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Otlertuzumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Pelabresib |
BET Bromodomain Inhibitor | Hematologic (MPN) | ||
|
Molecule
Pelabresib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
BET Bromodomain Inhibitor |
||||
Petosemtamab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Petosemtamab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Pinatuzumab Vedotin |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Pinatuzumab Vedotin
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Plinabulin |
Tubulin-Binding Agent / GEF-H1 Activator | Both (Solid & Hematologic) | ||
|
Molecule
Plinabulin
Therapeutic Category
Supportive Care (Investigational Growth Factor Alternative)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Tubulin-Binding Agent / GEF-H1 Activator |
||||
PRN1371 (Investigational FGFR) |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
PRN1371 (Investigational FGFR)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Raludotatug Deruxtecan |
Anti-CDH6 ADC, Topoisomerase I Inhibitor Payload | Solid Tumour | ||
|
Molecule
Raludotatug Deruxtecan
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-CDH6 ADC, Topoisomerase I Inhibitor Payload |
||||
NX-2127 (BTK Degrader)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
|
NX-5948 (BTK Degrader)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
|
ObrixtamigImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Bispecific T-Cell Engager, DLL3 x CD3 |
|
OciperlimabImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|
OmburtamabTargeted Therapy (Investigational Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody)
Oncology Type
Solid Tumour (Neuroblastoma)
Drug Class / Mechanism
Radiolabelled Anti-B7-H3 Monoclonal Antibody (I-131) |
|
OtlertuzumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
PelabresibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
BET Bromodomain Inhibitor |
|
PetosemtamabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Pinatuzumab VedotinTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
PlinabulinSupportive Care (Investigational Growth Factor Alternative) |
|
|
Therapeutic Category
Supportive Care (Investigational Growth Factor Alternative)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Tubulin-Binding Agent / GEF-H1 Activator |
|
PRN1371 (Investigational FGFR)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
Raludotatug DeruxtecanTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-CDH6 ADC, Topoisomerase I Inhibitor Payload |
|